4.43
price up icon32.24%   1.08
after-market Dopo l'orario di chiusura: 4.43
loading
Precedente Chiudi:
$3.35
Aprire:
$4.22
Volume 24 ore:
8.83M
Relative Volume:
9.85
Capitalizzazione di mercato:
$246.77M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-7.9107
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
+22.38%
1M Prestazione:
+50.68%
6M Prestazione:
-53.12%
1 anno Prestazione:
+118.23%
Intervallo 1D:
Value
$3.93
$4.49
Intervallo di 1 settimana:
Value
$3.165
$4.49
Portata 52W:
Value
$1.75
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Nome
Corvus Pharmaceuticals Inc
Name
Telefono
(650) 900-4520
Name
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Name
Dipendente
31
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
CRVS's Discussions on Twitter

Confronta CRVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
4.43 246.77M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-02 Iniziato H.C. Wainwright Buy
2023-08-18 Iniziato Oppenheimer Outperform
2021-12-01 Ripresa Jefferies Buy
2021-05-27 Iniziato Cantor Fitzgerald Overweight
2021-02-10 Downgrade Mizuho Buy → Neutral
2019-09-12 Iniziato Mizuho Buy
2019-05-29 Iniziato ROTH Capital Buy
2017-08-24 Aggiornamento Credit Suisse Underperform → Neutral
2017-05-01 Downgrade Credit Suisse Neutral → Underperform
2016-04-18 Iniziato Credit Suisse Outperform
2016-04-18 Iniziato Guggenheim Buy
Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

pulisher
May 10, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable

May 09, 2025
pulisher
May 09, 2025

Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results - Investing.com

May 09, 2025
pulisher
May 09, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Corvus: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Post-Trade Analysis: Corvus Pharmaceuticals Inc (CRVS) Slides -6.03, Closing at 3.35 - DWinneX

May 07, 2025
pulisher
May 02, 2025

Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com

May 02, 2025
pulisher
Apr 30, 2025

CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel

Apr 30, 2025
pulisher
Apr 30, 2025

Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com

Apr 30, 2025
pulisher
Apr 29, 2025

Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX

Apr 29, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News

Apr 25, 2025
pulisher
Apr 24, 2025

Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune

Apr 24, 2025
pulisher
Apr 23, 2025

Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan

Apr 23, 2025
pulisher
Apr 21, 2025

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister

Apr 21, 2025
pulisher
Apr 10, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - The Manila Times

Apr 10, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints New Director to Board - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN

Apr 07, 2025
pulisher
Mar 29, 2025

Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025

Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Capitalizzazione:     |  Volume (24 ore):